inclusion criteria: 1. patient admitted to hospital due to the severity of his/her confirmed or suspected covid-19 disease. 2. positive virus test for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using real time polymerase chain reaction (nasal swab). 3. patient with covid-19 clinical progression scale score ≥ 4 (hospitalized; no oxygen therapy). 4. male or female, ≥18 years of age at the time of consent. 5. patients who have given written informed consent. 6. reliable patients who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures. 7. patients who have the ability to understand the requirements of the clinical trial. 8. female patients of childbearing potential (women of childbearing potential, wocbp ) should have a negative pregnancy test at screening visit. 9. female patients of childbearing potential (women of childbearing potential, wocbp1) using a highly effective method of contraception (i.e., pregnancy rate of \< 1% per year) on a stable regimen, for at least 28 days, and pursuing this contraception during the trial and for 28 days after the last administration of the study drug the highly effective methods of contraception must be one of the following: combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agreement on continuous abstinence from heterosexual intercourse.

inclusion criteria: 1. patient admitted to hospital due to the severity of his/her confirmed or suspected covid-19 disease. 2. positive virus test for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using real time polymerase chain reaction (nasal swab). 3. patient with covid-19 clinical progression scale score ≥ 4 (hospitalized; no oxygen therapy). 4. male or female, ≥18 years of age at the time of consent. 5. patients who have given written informed consent. 6. reliable patients who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures. 7. patients who have the ability to understand the requirements of the clinical trial. 8. female patients of childbearing potential (women of childbearing potential, wocbp ) should have a negative pregnancy test at screening visit. 9. female patients of childbearing potential (women of childbearing potential, wocbp1) using a highly effective method of contraception (i.e., pregnancy rate of \< 1% per year) on a stable regimen, for at least 28 days, and pursuing this contraception during the trial and for 28 days after the last administration of the study drug the highly effective methods of contraception must be one of the following: combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agreement on continuous abstinence from heterosexual intercourse.

inclusion criteria: patient admitted to hospital due to the severity of his/her confirmed or suspected covid-19 disease. positive virus test for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using real time polymerase chain reaction (nasal swab). patient with covid-19 clinical progression scale score ≥ 4 (hospitalized; no oxygen therapy). male or female, ≥18 years of age at the time of consent. patients who have given written informed consent. reliable patients who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures. patients who have the ability to understand the requirements of the clinical trial. female patients of childbearing potential (women of childbearing potential, wocbp ) should have a negative pregnancy test at screening visit. female patients of childbearing potential (women of childbearing potential, wocbp1) using a highly effective method of contraception (i.e., pregnancy rate of < 1% per year) on a stable regimen, for at least 28 days, and pursuing this contraception during the trial and for 28 days after the last administration of the study drug the highly effective methods of contraception must be one of the following: combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agreement on continuous abstinence from heterosexual intercourse.

inclusion criteria: patient admitted to hospital due to the severity of his/her confirmed or suspected covid-19 disease. positive virus test for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using real time polymerase chain reaction (nasal swab). patient with covid-19 clinical progression scale score ≥ 4 (hospitalized; no oxygen therapy). male or female, ≥18 years of age at the time of consent. patients who have given written informed consent. reliable patients who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures. patients who have the ability to understand the requirements of the clinical trial. female patients of childbearing potential (women of childbearing potential, wocbp ) should have a negative pregnancy test at screening visit. female patients of childbearing potential (women of childbearing potential, wocbp1) using a highly effective method of contraception (i.e., pregnancy rate of < 1% per year) on a stable regimen, for at least 28 days, and pursuing this contraception during the trial and for 28 days after the last administration of the study drug the highly effective methods of contraception must be one of the following: combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agreement on continuous abstinence from heterosexual intercourse.

inclusion criteria: 1. patient admitted to hospital due to the severity of his/her confirmed or suspected covid-19 disease. 2. positive virus test for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using real time polymerase chain reaction (nasal swab). 3. patient with covid-19 clinical progression scale score ≥ 4 (hospitalized; no oxygen therapy). 4. male or female, ≥18 years of age at the time of consent. 5. patients who have given written informed consent. 6. reliable patients who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures. 7. patients who have the ability to understand the requirements of the clinical trial. 8. female patients of childbearing potential (women of childbearing potential, wocbp ) should have a negative pregnancy test at screening visit. 9. female patients of childbearing potential (women of childbearing potential, wocbp1) using a highly effective method of contraception (i.e., pregnancy rate of < 1% per year) on a stable regimen, for at least 28 days, and pursuing this contraception during the trial and for 28 days after the last administration of the study drug the highly effective methods of contraception must be one of the following: combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agreement on continuous abstinence from heterosexual intercourse.

inclusion criteria: 1. patient admitted to hospital due to the severity of his/her confirmed or suspected covid-19 disease. 2. positive virus test for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using real time polymerase chain reaction (nasal swab). 3. patient with covid-19 clinical progression scale score ≥ 4 (hospitalized; no oxygen therapy). 4. male or female, ≥18 years of age at the time of consent. 5. patients who have given written informed consent. 6. reliable patients who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures. 7. patients who have the ability to understand the requirements of the clinical trial. 8. female patients of childbearing potential (women of childbearing potential, wocbp ) should have a negative pregnancy test at screening visit. 9. female patients of childbearing potential (women of childbearing potential, wocbp1) using a highly effective method of contraception (i.e., pregnancy rate of < 1% per year) on a stable regimen, for at least 28 days, and pursuing this contraception during the trial and for 28 days after the last administration of the study drug the highly effective methods of contraception must be one of the following: combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agreement on continuous abstinence from heterosexual intercourse.